EXecutive: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS) in the Treatment of the Specific Setting of Patients With Multi-Vessel Coronary Artery Disease.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Everolimus (Primary) ; Paclitaxel
Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
Focus Therapeutic Use
Acronyms EXecutive
Sponsors Abbott Laboratories

10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
18 Sep 2009 Planned end date changed from 1 Sep 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
03 Jan 2008 Added trial centre from NCT last updated 3 Jan 2008.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com